Immune checkpoint inhibitors (ICIs) have dramatically improved patient outcomes in a
variety of tumor types, but with variable efficacy. Recent research has suggested that …

Purpose Pre-clinical and early clinical data suggests the microbiome plays an important role
in oncogenesis and influences response to immune checkpoint blockade (ICB). The …

Abstract Background Immune checkpoint inhibitors (ICIs) represent the standard of care as
first-or second-line treatment in patients with renal cell carcinoma (RCC). Proton pump …

Objectives Observational and experimental studies suggest that the use of antibiotics close
to administration of immune checkpoint inhibitors (ICI) can have a negative effect on tumour …

Introduction Gut microbiota can significantly affect the effectiveness of immune checkpoint
inhibitors (ICIs) in cancer patients. Recently, antibiotics were shown to decrease survival …

The gut microbiota influences the clinical responses of cancer patients to immunecheckpoint
inhibitors (ICIs). However, there is no consensus definition of detrimental dysbiosis. Based …

Abstract Objective Immune checkpoint inhibitors (ICIs) have recently achieved inspiring
performance in improving the prognosis of various solid tumors. Gut microbiome plays a …

Background Proton pump inhibitors (PPIs) are commonly prescribed for preventing and
treating gastrointestinal ulcers. In patients with advanced cancer, it is unclear whether …

The gastrointestinal microbiome has been shown to play a key role in determining the
responses to cancer immunotherapy, including immune checkpoint inhibitor (ICI) therapy …

Antibiotic (ATB) use seems to negatively affect the outcomes of immune checkpoint
inhibitors (ICIs). The aim of this review is to clarify whether ATB use influences the efficacy of …